A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells — which can give rise to every cell type in the body and which can be grown indefinitely in the lab — into becoming mature T cells capable of killing tumor cells.

A new study by UCLA scientists shows that enhancers, snippets of DNA that contribute to gene regulation, fall into the same “insulated neighborhoods” or chromatin loops as the target gene and other gene-specific regulatory elements.

Researchers from the UCLA Jonsson Comprehensive Cancer Center and the La Jolla Institute of Immunology have identified a new type of T cell called a phospholipid-reactive T cell that is able to recognize phospholipids, the molecules that help form cells’ outer membranes.

Carla Koehler, a professor with the Department of Chemistry and Biochemistry, has been named a Fellow of the American Association for the Advancement of Science. Koehler’s election is an honor bestowed on her by her peers within the Association.

The newly FDA-approved larotrectinib is a targeted cancer therapy. UCLA treated “Little Linda” as part of a trial. She had infantile fibrosacoma. Within days of beginning her treatment, the tumor started shrinking.

UCLA researchers conducted a study of breast cancer survivors to better understand if lower activity of telomerase (an enzyme that helps maintain the health of cells) along with DNA damage (a factor in cellular aging) were associated with worse cognitive performance, such as attention and motor skills.

A group of researchers from the UCLA Jonsson Comprehensive Cancer Center received a $3.5 million, five-year grant from the National Institute of Health to create a center dedicated to developing an effective and affordable blood-based cancer-screening test to help detect liver cancer early.

Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists.

Denise Delatorre felt a lump in her stomach that she knew was serious. She was diagnosed with non-Hodgkin’s lymphoma, one of the most common blood cancers. When chemotherapy didn’t work, she enrolled in UCLA’s first CAR T clinical trial. Today, Denise is in sustained remission. This is her story.

UCLA researchers have discovered a new protein factor that contributes to a fibroblast cell’s ability to migrate to a wound and participate in its healing process. The study’s results could help scientists prevent cancer cells from using the same mechanisms to move throughout the body and spread.

UCLA researchers have discovered a new protein factor that contributes to a fibroblast cell’s ability to migrate to a wound and participate in its healing process. The study’s results could help scientists prevent cancer cells from using the same mechanisms to move throughout the body and spread.